Form 4 for LCTX Lineage Cell Therapeutics, Inc.

Accepted 2025-12-19 00:00:00 ET · period of report 2025-12-19 · accession 0001193125-25-327280 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
	2025-12-19	2025-12-19	LCTX	Culley Brian M	Pres, CEO, Dir	A - Grant	—	+8,925	222.5K	+4%	—
	2025-12-19	2025-12-19	LCTX	Culley Brian M	Pres, CEO, Dir	F - Tax	$1.68	-334	222.1K	-0.2%	-$561.12

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Shares	2025-12-19	A	A	8,925	—	222,469	D	—	—	(F1) Shares earned by the Reporting Person upon the vesting of a portion of restricted stock units ("RSUs") granted to the Reporting Person on February 11, 2022 the vesting of which was subject to the achievement of certain performance conditions. RSUs are settled in common shares on a one-for-one basis. (F2) Does not include RSUs that may be settled in the issuer's common shares that have not vested as of the date hereof nor common shares that may be acquired upon the exercise of certain stock options outstanding as of the date hereof.
2	Common	Common Shares	2025-12-19	F	D	334	$1.68	222,135	D	—	—	(F3) Shares withheld by the issuer to satisfy statutory tax withholding requirements on the vesting of 8,925 RSUs in a transaction exempt under Rule 16(b)-3. No shares were sold in connection with this transaction. (F2) Does not include RSUs that may be settled in the issuer's common shares that have not vested as of the date hereof nor common shares that may be acquired upon the exercise of certain stock options outstanding as of the date hereof.